RBC Capital Maintains Biogen at Outperform, Raises Target to $272
RBC Capital maintained its Outperform rating on Biogen and raised its price target to $272 from $256.
Story updates
07:30:41 PM UTC
SquawkNews
Biogen Is Maintained at Outperform by RBC Capital